Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Rectal Adenocarcinoma clinical trials
Every US clinical trial registered for Metastatic Rectal Adenocarcinoma — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
7 US clinical trials ·
The research picture
Metastatic Rectal Adenocarcinoma has 7 registered US clinical trials; none are currently listed as recruiting, so most are completed or in follow-up.
- 0
- recruiting participants now
- 0%
- of trials open to enrollment
- 0
- in Phase 3–4 (later-stage)
- 4
- top sponsor: M.D. Anderson Cancer Center
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer
M.D. Anderson Cancer Center
NCT02874885
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
NCT05308446
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
NCT04599140
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
NCT04616183
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
NCT04017650
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
NCT05627635
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
NCT03992456
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Metastatic Rectal Adenocarcinoma Trial Landscape
ClinicalTrials.gov lists 7 US studies indexed under Metastatic Rectal Adenocarcinoma, and 0 of those are currently open to recruitment — roughly 0% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Metastatic Rectal Adenocarcinoma shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 6 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Metastatic Rectal Adenocarcinoma is led by M.D. Anderson Cancer Center with 4 indexed trials, alongside 3 other organizations in the top contributor list. The list on this page surfaces up to 7 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Metastatic Rectal Adenocarcinoma?
PlainTrial tracks 7 US clinical trials for Metastatic Rectal Adenocarcinoma, of which 0 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Metastatic Rectal Adenocarcinoma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.